Skip to main content
OpenTrials
Completed

NCT Number: NCT00185991

Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis

To compare once daily versus 8 hour dosing of gentamicin for the treatment of chorioamnionitis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chorioamnionitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Female Urogenital Diseases and Pregnancy Complications Fetal Diseases Fetal Membranes, Premature Rupture Obstetric Labor Complications Placenta Diseases Pregnancy Complications Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • clinical diagnosis of chorioamnionitis

Exclusion criteria

  • maternal renal disease, intrauterine fetal death, allergy to gentamicin

Treatment and study plan

Gentamicin

Drug

Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).

Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours).

Primary outcomes

  1. Afebrile at 24 hours and no endometritis

    Time frame: 24 hours after delivery

Secondary outcomes

  1. Neonatal outcomes

    Time frame: Time of delivery to time of discharge

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start
2004
Primary completion
2006
Study completion
2010
First posted
Sep 16, 2005
Registry last updated
Jun 15, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.